Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trialSTX-478 could potentially address 30-40% of people with hormone-positive breast cancer, building on Lilly's advancements against this diseaseINDIANAPOLIS and BOSTON, Mass., Jan. 13, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company develop ...